Interestingly, the top three sales of peptide drugs were all GLP-1 analogues for treating T2DM, including Trulicity (dulaglutide) ranked at 19 with $4.39 billion retail sales, Victoza (liraglutide), ranked at 32 with $3.29 billion sales, and Rybelsus (semaglutide), ranked at 83 with $1.68 billion sales (Fig. 1). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.